Ophthalmology | Phase III Developments

Outlook Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

Lead Product(s): Bevacizumab

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BioLexis Pte. Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 28, 2020

Details:

Outlook Therapeutics signed agreement with BioLexis Pte. Ltd to better align the interests of all parties with common stockholders of the Company and to help ONS-5010's continuing development.

Bausch Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal inje...

Lead Product(s): Triamcinolone Acetonide

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The data demonstrated that patients with noninfectious uveitis in the XIPERE study arm experienced clinically significant improvement in vision relative to the control arm.

Aldeyra Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis

Lead Product(s): Reproxalap

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

The INVIGORATE Trial, which will enroll approximately 120 patients aims to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared with vehicle using an allergen chamber.